Irinotecan (CPT-11) HCl Trihydrate - 10mM in DMSO , DNA topoisomerase I inhibitor, CAS No.136572-09-3, DNA topoisomerase I inhibitor

CAS: 136572-09-3 Cat. No.: I408334 Molecular Weight: 677.18 EC Number: 603-967-2 PubChem CID: 60837

GRADE & PURITY 10mM in DMSO

Synonyms

[1,​4'-​Bipiperidine]​-​1'-​carboxylic acid, (4S)​-​4,​11-​diethyl-​3,​4,​12,​14-​tetrahydro-​4-​hydroxy-​3,​14-​dioxo-​1H-​pyrano[3',​4':6,​7]​indolizino[1,​2-​b]​quinolin-​9-​yl ester, hydrochloride, hydrate (1:1:3)

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

Irinotecan (CPT-11) prevents DNA from unwinding by inhibition oftopoisomerase 1.
In vitro

Irinotecan is activated to SN-38 by carboxylesterases to become able to interact with its target, topoisomerase I. Irinotecan induces similar amounts of cleavable complexes at its IC50 in LoVo cells and HT-29 cell lines. SN-38 induces a concentration-dependent formation of cleavable complexes, which is not significantly different in LoVo cells and HT-29 cell lines. Cell accumulation of Irinotecan is markedly different, reaching consistently higher levels in HT-29 cells than in LoVo cells. The lactone E-ring of Irinotecan and SN-38 hydrolyses reversibly in aqueous solutions, and the interconversion between the lactone and carboxylate forms is dependent on pH and temperature. Liver is primarily responsible for the activation of Irinotecan to SN-38. At equal concentrations of Irinotecan and SN-38 glucuronide, the rate of beta-glucuronidase-mediated SN-38 production is higher than that formed from Irinotecan in both tumour and normal tissue. Irinotecan is also converted to SN-38 in intestines, plasma and tumor tissues. Irinotecan is significantly more active in SCLC than in NSCLC cell lines, whereas no significant difference between histological types is observed with SN-38.

In vivo

In COLO 320 xenografts, Irinotecan induces a maximum growth inhibition of 92%. A single dose of Irinotecan significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver. Concomitantly, the Irinotecan-treated group shows significantly higher amounts of DNA strand breaks in colon mucosa cells compared to the control group.
Cell Data

cell lines：

Concentrations：0 μM -100 μM

Incubation Time：48 hours

Powder Purity:≥99%

Specifications

Synonyms

[1, ​4'-​Bipiperidine]​-​1'-​carboxylic acid, (4S)​-​4, ​11-​diethyl-​3, ​4, ​12, ​14-​tetrahydro-​4-​hydroxy-​3, ​14-​dioxo-​1H-​pyrano[3', ​4':6, ​7]​indolizino[1, ​2-​b]​quinolin-​9-​yl ester, hydrochloride, hydrate (1:1:3)

Specifications & Purity

10mM in DMSO

Biochemical and Physiological Mechanisms

Irinotecan (CPT-11) prevents DNA from unwinding by inhibition of topoisomerase 1.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Action Type

INHIBITOR

Mechanism of action

DNA topoisomerase I inhibitor

Names and Identifiers

• Isomeric SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.O.O.O.Cl
• RTECS: DW1060750
• PubChem CID: 60837
• Molecular Weight: 677.18
• Reaxy-Rn: 4838283

Chemical and Physical Properties

• Solubility: Solubility (25°C) In vitro DMSO: 71 mg/mL (200.63 mM); Water: 16 mg/mL (45.21 mM); Ethanol: 15 mg/mL (42.38 mM)
• Specific Rotation[α]: 24° (C=1,MeOH)
• Boil Point(°C): 257°C

References

1. Xiawei Zhou, Xiuhua Pan, Ziqi Shen, Ruixin Kang, Yueru Pang, Lin Luo, Feiyang Liu, Siyuan Yu, Jun Zhang, Qi Shen.  (2025)  Eliminating intratumoral bacteria with cGAS-STING-activating nanodrug-bacteria biohybrids potentiates cancer immunotherapy.  BIOMATERIALS,      [PMID:40818326] [10.1016/j.biomaterials.2025.123629]

2. Xinxin Meng, Zhun Liu, Xubin Qian, Shaoyu Tang, Cheng Fang, Junfeng Niu, Lei Xu.  (2022)  Enhanced degradation mechanism of anticancer drug irinotecan through low-frequency ultrasound assisted reactive electrochemical membrane.  Journal of Cleaner Production,      [PMID:] [10.1016/j.jclepro.2022.135419]

3. Yongfa Jing, Dongli Yan.  (2025)  Modulation of gut microbiota and immune response by soy peptides mitigates irinotecan induced intestinal toxicity.  Frontiers in Physiology,      [PMID:40529994] [10.3389/fphys.2025.1538733]